Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | BAX | Q07812 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869613 | 0.89 | MAPK1 (0.32) | MAPK1PRMT5WDR77 | |
| SCHEMBL14808960 | 0.83 | PRMT5 (0.41) | PRMT5WDR77TP53MAPTMEN1 | |
| SCHEMBL30869712 | 0.81 | PIM1 (0.41) | MAPTMEN1KMT2AAHR | |
| SCHEMBL30869631 | 0.79 | PIM1 (0.35) | AHR | |
| SCHEMBL30869647 | 0.79 | PIM1 (0.35) | AHR | |
| SCHEMBL30869781 | 0.78 | PIM1 (0.35) | AHR | |
| SCHEMBL30869404 | 0.77 | KMT2A (0.33) | MAPK1BAXPRMT5WDR77TP53 | |
| SCHEMBL30869465 | 0.76 | TSHR (0.36) | MEN1KMT2ATSHRAHR | |
| SCHEMBL30869833 | 0.76 | PRMT5 (0.39) | MAPK1PRMT5WDR77 | |
| SCHEMBL14823908 | 0.74 | RAD52 (0.35) | PRMT5WDR77RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | MAPK1 715/4885BAX 1339/4885PRMT5 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.